Samantha Mraz
Psychiatric/Mental Health · Bridgeport, CTNPI 1013484088
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,944 of the $86,520 with a category attached, or 63.5%. Neurocrine Biosciences, Inc. accounts for 87.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $46,287, more than ten times the $565 reported in 2022. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $336.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$75K
- AbbVie$9K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- E.r. Squibb & Sons, L.L.C.$452
- Teva Pharmaceuticals USA, Inc.$308
- Alkermes, Inc.$223
- plus $538 from 8 others
What the payments were for
- Consulting fees$17,06320%
- Speaking & faculty fees$54,94464%
- Travel & lodging$6,8358%
- Food & beverage$7,6179%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 124 | $75,301 |
| AbbVie | 39 | $8,644 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $1,054 |
| E.r. Squibb & Sons, L.L.C. | 16 | $452 |
| Teva Pharmaceuticals USA, Inc. | 13 | $308 |
| Alkermes, Inc. | 8 | $223 |
| Otsuka America Pharmaceutical, Inc. | 14 | $219 |
| Vanda Pharmaceuticals Inc. | 5 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $92 |
| Johnson & Johnson | 1 | $34 |
| Lundbeck LLC | 1 | $24 |
| GSK | 1 | $22 |
| Tempus AI, Inc | 1 | $19 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,520 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $180,609 |
| Lurasidone Hcl | 65 | $12,378 |
| Duloxetine Hcl | 27 | $1,590 |
| Hydroxyzine Pamoate | 56 | $1,525 |
| Olanzapine | 39 | $1,370 |
| Quetiapine Fumarate | 88 | $1,216 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,110 |
| Haloperidol | 33 | $1,092 |
| Buspirone Hcl | 71 | $1,042 |
| Divalproex Sodium ErDivalproex Sodium | 46 | $931 |
| Prazosin Hcl | 35 | $895 |
| Mirtazapine | 44 | $818 |
| Propranolol Hcl | 26 | $590 |
| Gabapentin | 35 | $541 |
| Zolpidem Tartrate | 40 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $75,301 | $180,60922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in Bridgeport
- Cristina MeehanNew Britain$224K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
- Max Greger-MoserNew Haven$15K
- Richard ComshawRocky Hill$14K
- John PalmaHamden$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.